drugset / Trial / NCT02411110

A Safety and Efficacy Study of LiRIS® in Females With Interstitial Cystitis/Bladder Pain Syndrome

NCT02411110

Phase 2 Completed 131 enrolled Allergan
RandomizedParallel-groupDouble-blindTreatment

Summary

This is a safety and efficacy study of LiRIS® in females with interstitial cystitis/bladder pain syndrome.

Timeline

Start
2015-05-21
Primary completion
2016-10-12
Completion
2017-01-09

Drugs

EvaluationDrugModalityDoseRoute
Subject Lidocaine Other / unclassified 400 mg Other

Indications